Page last updated: 2024-08-17

medroxyprogesterone acetate and Osteosarcoma

medroxyprogesterone acetate has been researched along with Osteosarcoma in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Bunce, CM; Ellington, MA; Johnson, WE; Khanim, FL; MacKay, HL; Sheard, JJ; Snow, MD; Southam, AD	1

Other Studies

1 other study(ies) available for medroxyprogesterone acetate and Osteosarcoma

Article	Year
Combined bezafibrate, medroxyprogesterone acetate and valproic acid treatment inhibits osteosarcoma cell growth without adversely affecting normal mesenchymal stem cells. Bioscience reports, 2021, 01-29, Volume: 41, Issue:1 Topics: Bezafibrate; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Repositioning; Drug Therapy, Combination; Fatty Acid Synthases; Humans; Medroxyprogesterone Acetate; Mesenchymal Stem Cells; Osteosarcoma; Stearoyl-CoA Desaturase; Up-Regulation; Valproic Acid	2021

Article

Year

Combined bezafibrate, medroxyprogesterone acetate and valproic acid treatment inhibits osteosarcoma cell growth without adversely affecting normal mesenchymal stem cells.

Bioscience reports, 2021, 01-29, Volume: 41, Issue:1

Topics: Bezafibrate; Bone Neoplasms; Cell Line, Tumor; Cell Proliferation; Down-Regulation; Drug Repositioning; Drug Therapy, Combination; Fatty Acid Synthases; Humans; Medroxyprogesterone Acetate; Mesenchymal Stem Cells; Osteosarcoma; Stearoyl-CoA Desaturase; Up-Regulation; Valproic Acid

2021